Skip to content

India Slashes Prices of Over a Thousand Anti-Cancer Formulations

By News Analysis India · · 1 min read

Delhi, 9 November 2026 – Effective from Monday, the Indian government has implemented a sweeping reduction in the maximum retail price of 1,364 anti‑cancer drug formulations. The move, announced by the National Pharmaceutical Pricing Authority (NPPA) on the basis of expert committee advice, aims to make life‑saving oncology medicines far more affordable for patients.

A total of 85 pharmaceutical firms reported revised MRPs for 121 distinct drugs, collectively covering all listed formulations. Out of the 1,364 brand‑specific products, 679 have seen price cuts exceeding 50 percent. The most dramatic decline, a 96.45 percent reduction, means a few medicines now cost less than one‑tenth of their former price.

The Ministry of Health projects that the cumulative annual savings for Indian households will be roughly ₹3,540.38 crore. This figure reflects the direct impact of lower drug costs on millions of cancer patients and their families.

To ensure transparency, the new MRPs are printed on each drug package. Buyers can also verify the correct price through the Pharma Sahi Daam app or the NPPA’s official website. Retail chemists and hospital pharmacies are barred from demanding a higher amount; any deviation will be considered a breach of the price‑control rules.

Consumers with complaints about overcharging can submit details via the Consumer Pharma Jan Samadhan portal or call the dedicated helpline at 1800‑111‑255 for assistance.